…in my view if this had been a private company, salaries would have been cut bearing in mind the financial situation of the company. The Remuneration Resolution got 202m votes…
…rush to sell). The Chairman, Barry Ariko, said the company might want to stay on the AIM market. Another shareholder said the company raised “a lot of money last year”….
…Company Fuller details and benefits are available in the 2011 report “Bridging the UK engagement gap through Swedish-style nomination committees”. The report can be found at Tomorrow’s-Company-Paper. For more information…
…given was that the company has few patents being mainly dependent on copyright for IP protection. The company also already uses R&D tax credits extensively to reduce its overall corporation…
…in the company; Enable the company to communicate more effectively with its ultimate owners; Enable ultimate investors to communicate with company management whenever they choose in their capacity as a…
…Institute of Company Directors. European Green Transition plc (EGT) European Green Transition plc is a business operating in the green economy transition space in Europe. EGT intends to capitalise on…
…timely and cost-effective manner for the benefit of global healthcare. Clients of the Company are developing a number of new drugs in which the Company has been involved. Presenter: Dr…
…Pharma PLC (N4P) N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. RNA therapeutics are set to…
…of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble…
…made serious allegations against the company. Key allegations, from the investor perspective, were that property valuations were overstated and future income was at risk. The company published a brief rebuttal…
…redemption). There is also an “Alternative Offer” to receive non-voting shares in the new private company, which are equally illiquid. The bidders, who already control ~63% of the company, have…
ShareSoc Growth Company Seminar (IN-PERSON EVENT), Leeds 8 October 2025 5pm Featuring: N4 Pharma PLC (N4P), Built Cybernetics plc (BUC), Aptamer Group plc (APTA) and One Health Group plc (OHGR)…
